FOXO4-DRI (D-Retro-Inverso) from Super Human Peptides UK is a pioneering senolytic peptide designed to selectively target and eliminate senescent cells—often referred to as "zombie cells." In laboratory research, FOXO4-DRI is studied for its ability to disrupt the interaction between the FOXO4 transcription factor and the p53 tumour suppressor protein. In senescent cells, FOXO4 typically sequesters p53 in the nucleus to prevent cell death.
By interfering with this bond, FOXO4-DRI allows p53 to translocate to the mitochondria and trigger apoptosis (programmed cell death) specifically in damaged cells, while leaving healthy, non-senescent cells unharmed. Produced under GMP-compliant conditions and verified for 99% purity or higher, FOXO4-DRI is a vital tool for advanced research into tissue rejuvenation and the biology of aging.
- —Targeted Senolytic: Selectively induces apoptosis in senescent cells.
- —D-Retro-Inverso (DRI) Modification: Engineered for high metabolic stability and potency.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Documentation: Full Certificate of Analysis (COA) provided with each batch.
- —Senescent Cell Clearance: Targeted apoptosis of aging fibroblasts and chondrocytes.
- —P53 Pathway Modulation: Research into nuclear exclusion and mitochondrial translocation of p53.
- —Tissue Homeostasis: Studies on the restoration of organ function (kidney, liver, and skin) in aged models.
- —Secretory Phenotype (SASP): Investigating the reduction of pro-inflammatory cytokines released by "zombie cells."
- —Metabolic Rejuvenation: Research into improving the testicular microenvironment and hormonal balance in aged subjects.
FOXO4-DRI gained international scientific attention through research published in the journal "Cell" by Baar et al. (2017). The study demonstrated that regular administration in aging mice could restore hair density, improve renal function, and enhance physical activity by clearing the burden of senescent cells.
Further research has explored its utility in specific tissues, including the restoration of high-quality cartilage formation and the improvement of Leydig cell function to support healthy testosterone levels in aged animal models. Unlike general chemotherapy agents, FOXO4-DRI is noted for its high specificity, significantly reducing the "SASP" (Senescence-Associated Secretory Phenotype) that typically drives systemic inflammation.
- 1.Baar, M.P. et al., "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging," Cell, 2017.
- 2.Zhang, C. et al., "FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells," Aging (Albany NY), 2020.
- 3.Hu, Z. et al., "FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway," Frontiers in Bioengineering and Biotechnology, 2025.
- 4.Doti, N. et al., "Recent Applications of Retro-Inverso Peptides," International Journal of Molecular Sciences, 2021.
